Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors. Wu TC, Lin CC. J Thorac Oncol 2022;17:1063-1066.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wu TC, Lin CC. Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors. J Thorac Oncol 2022;17:1063-1066.
PMID: 36031284